SOUTH PLAINFIELD, N.J., Oct. 24, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced new results from its investigational gene therapy, PTC-AADC, in patients living with ...
On March 12, 2026, the U.S. Court of Appeals for the Ninth Circuit released an opinion that partially vacates a lower court’s injunction of the California Age-Appropriate Design Code Act (AADC), ...
The Food and Drug Administration (FDA) has granted accelerated approval to Kebilidi™ (eladocagene exuparvovec-tneq) for the treatment of adult and pediatric patients with aromatic L-amino acid ...
SOUTH PLAINFIELD, N.J., Aug. 23, 2021 /PRNewswire/ — PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the publication of a manuscript, “Gene Therapy in the Putamen for Curing AADC Deficiency and ...
CAMBRIDGE, Mass., Dec. 22, 2020 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR) today announced that the U.S. Food and Drug Administration (FDA) has notified Neurocrine Biosciences ...
Targeting the Putamen with Gene Therapy Leads to Sustained Improvements in Motor and Non-Motor Functions in Children with AADC Deficiency SOUTH PLAINFIELD, N.J., Aug. 23, 2021 – PTC Therapeutics, Inc.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results